Nanotherapeutic that can cross blood-brain barrier reported in journal
The University of Delaware’s Emily Day is a part of a team of researchers that has developed a nanotherapeutic capable of penetrating the blood-brain barrier.
Previously believed impossible, the groundbreaking development could have implications in the treatment of Glioblastoma multiforme (GBM), a lethal form of malignant brain tumors that is considered one of the deadliest human cancers. It may also benefit research for neurodegenerative diseases such as Parkinson’s disease, traumatic brain injury and multiple forms of cancer.
Led by researchers at Northwestern University, where Day conducted post-doctoral research, the team discovered that spherical nucleic acids (SNAs), tiny spherical gold nanoparticles densely coated with nucleic acids, have unique properties that allow them to pass through the blood-brain barrier and attack brain cancer.
The technology works by targeting Bcl2L12, a gene important in tumor progression.
“We believe that the SNA particles pass through by binding to scavenger receptors present in the cells lining the blood-brain barrier,” Day explained. “Once past the barrier, the SNA particles travel through the brain tissue and infiltrate tumor cells, where they interfere with the tumor cell’s genetic machinery to prevent the Bcl2L12 gene from being expressed.”
When administered systemically in cell and rodent models, the SNAs delivered nucleic acids to tumors without help from cationic carriers or other chemical modifications, lowered the expression of Bcl2L12 and effectively reduced tumor burden.
“Generally speaking we saw about a 20 percent increase in animal survival rates with this treatment, and a five-fold reduction in tumor growth without adverse side effects,” said Day, assistant professor of biomedical engineering at UD.
This discovery establishes SNAs as a promising new class of therapeutic gene regulation agents capable of treating disease through systemic injection, according to the research team’s findings published as a cover article in Science Translational Medicine, a publication of the American Association for the Advancement of Science.
Co-first authors on the paper were Day, Samuel Jensen and Caroline Ko, and their interdisciplinary team included researchers from Northwestern University’s departments of chemistry, biomedical engineering, molecular biosciences, neurology, neurobiology, and the International Institute for Nanotechnology. The research was led by Chad Mirkin, professor in Northwestern University’s Department of Chemistry, and Alexander Stegh, professor, in the Department of Neurology.
Future work on the project will include studies to determine safety and efficacy issues necessary for human trials and scaling the technology for manufacturing.
The Latest Google Headlines on:
Brain cancer
[google_news title=”” keyword=”Brain cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Brain cancer
- Some brain tumors may be linked to head injury, mouse study suggestson May 9, 2024 at 9:27 am
A study in mice by researchers at the School of Medicine indicates that brain injury can lead to brain tumors in susceptible individuals. For this study, they used mice that model people with neurofibromatosis type 1 (NF1), a genetic disorder that causes ...
- RFK Jr. says doctors found a dead worm in his brain. Here's how it happens and why it's rare in the U.S.on May 8, 2024 at 2:58 pm
Kennedy Jr. says he is living with a dead worm in his brain, according to court documents obtained by the New York Times. Kennedy, 70, said the remains of the parasite were discovered in 2010 after he saw a neurologist for memory loss and brain fog,
The Latest Google Headlines on:
Nanotherapeutic
[google_news title=”” keyword=”nanotherapeutic” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Nanotherapeutic
- Biomednewsbreaks Clene Inc. (NASDAQ: CLNN) Spotlighted In A Recent 'From Lab To Launch' Podcast Releaseon May 1, 2024 at 9:12 pm
Clene (NASDAQ: CLNN) (along with its subsidiaries,“Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biophar ...
- Nanotechnology opens door to future of insulin medicationon May 1, 2024 at 5:00 pm
The findings are published in Nature Nanotechnology ("Oral nanotherapeutic formulation of insulin with reduced episodes of hypoglycaemia"). It is estimated 422 million people worldwide have diabetes ...
- IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington | Morningstaron May 1, 2024 at 5:50 am
Throughout the interview, Etherington continued to discuss CNM-Au8, detailing both current and potential target applications for the nanotherapeutic, before exploring some of the challenges in ...
- IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etheringtonon May 1, 2024 at 5:30 am
LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob ...
- IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etheringtonon May 1, 2024 at 1:30 am
Throughout the interview, Etherington continued to discuss CNM-Au8, detailing both current and potential target applications for the nanotherapeutic, before exploring some of the challenges in ...
- The neglected epidemic: Meridius Bio tackles chronic wounds with its AIMER technologyon April 21, 2024 at 5:00 pm
Inspired by the concept of “programmable regeneration,” developed from Dr. Uri Galili’s important research and findings, their proprietary nanotherapeutic platform, Active Immuno-Modulated ...
- Biomednewsbreaks Clene Inc.'S (NASDAQ: CLNN) Work In Nanotechnology Highlighted In 'First In Human' Podcaston March 19, 2024 at 7:14 am
We at Clene had the idea to combine this with the mechanism of a nanotherapeutic, providing, at the atomic level, the ability to drive energy into the failing mitochondria that powers your and my ...
- Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours (IMAGE)on October 23, 2023 at 9:05 am
The schematics of inflammation-induced neutrophil movement breaking through BM and cause explosive release of NPs. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news ...
- Nanotechnology to fight and cure canceron August 13, 2020 at 10:00 pm
Making use of nanotechnology materials and applications, theranostic nanomedicine can be understood as an integrated nanotherapeutic system, which can diagnose, deliver targeted therapy and monitor ...
- Daniel A. Heller: Publicationson August 20, 2018 at 7:12 pm
DA Heller*: “P-selectin is a Nanotherapeutic Delivery Target to the Tumor Microenvironment.” Science Translational Medicine 8 (2016) 345ra8 [Highlighted in Science Translational Medicine 8 (2016) ...